Updates are available Correction dated 2016-07-06
Click to view Correction: https://doi.org/10.1038/nature18939
Updates are available Correction dated 2016-07-06
Click to view Correction: https://doi.org/10.1038/nature18939
Updates are available Expression of concern dated 2023-08-07
Click to view Expression of concern: https://doi.org/10.1038/nature17392
Retraction Retraction dated 2025-10-29
Click to view Retraction: https://doi.org/10.1038/s41586-025-09719-z
-
Authors
Kaur, Amanpreet
Webster, Marie R.
Marchbank, Katie
Behera, Reeti
Ndoye, Abibatou
Kugel, Curtis H.
Dang, Vanessa M.
Appleton, Jessica
O’Connell, Michael P.
Cheng, Phil
Valiga, Alexander A.
Morissette, Rachel
McDonnell, Nazli B.
Ferrucci, Luigi
Kossenkov, Andrew V.
Meeth, Katrina
Tang, Hsin-Yao
Yin, Xiangfan
Wood, William H.
Lehrmann, Elin
Becker, Kevin G.
Flaherty, Keith T.
Frederick, Dennie T.
Wargo, Jennifer A.
Cooper, Zachary A.
Tetzlaff, Michael T.
Hudgens, Courtney
Aird, Katherine M.
Zhang, Rugang
Xu, Xiaowei
Liu, Qin
Bartlett, Edmund
Karakousis, Giorgos
Eroglu, Zeynep
Lo, Roger S.
Chan, Matthew
Menzies, Alexander M.
Long, Georgina V.
Johnson, Douglas B.
Sosman, Jeffrey
Schilling, Bastian
Schadendorf, Dirk
Speicher, David W.
Bosenberg, Marcus
Ribas, Antoni
Weeraratna, Ashani T.
- License Information
-
More Information
Article History
Received: 24 November 2014
Accepted: 2 February 2016
First Online: 4 April 2016
Change Date: 7 August 2023
Change Type: Update
Change Details: Editor’s Note: "Readers are alerted that the reliability of some of the data presented in this manuscript is currently in question. Appropriate editorial action will be taken once this matter is resolved."
Change Date: 29 October 2025
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41586-025-09719-z
Competing interests
: K.T.F. is a consultant to GlaxoSmithKline, Roche, and Novartis; G.V.L. is a consultant to Amgen, Bristol-Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Roche; J.A.W. is a consultant to Roche and GlaxoSmithKline. We do not believe these relationships have any direct impact on this work.
